Biomarker-Driven NSCLC Care: The Precision Medicine Model for Today and the Future

Learn more about current biomarkers you can use to personalize care for your patients with NSCLC with downloadable slides and an on-demand webcast from a live symposium and a ClinicalThought commentary answering audience questions from the live event.

Share

Program Content

Activities

NSCLC: Molecular Testing
The Importance of Molecular Testing in NSCLC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: April 11, 2022

Expires: April 10, 2023

NSCLC: <i>EGFR</i> and <i>KRAS</i>
Treatment Options for the Most Common Targetable Biomarkers for Advanced NSCLC: EGFR and KRAS
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: April 11, 2022

Expires: April 10, 2023

Less Common Driver Mutations in NSCLC
Selecting Therapy for Less Common Driver Mutations in Advanced Lung Cancer: ALK, ROS, RET, NTRK, MET
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: April 11, 2022

Expires: April 10, 2023

No activities added yet

Activities

NSCLC Biomarkers
Using Biomarkers to Guide NSCLC Care: An Expert Discussion
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: May 26, 2022

Expires: May 25, 2023

Faculty

cover img faculity

Todd M. Bauer, MD

Senior Investigator, Greco-Hainsworth Centers for Research
Tennessee Oncology, PLLC
Nashville, Tennessee

cover img faculity

Sandip P. Patel, MD

Professor, Medical Oncology, UC San Diego
Leader, Experimental Therapeutics
Deputy Director, Sanford Stem Cell Clinical Center
Co-Leader, Solid Tumor Therapeutics Program
Medical Director, Clinical Research Informatics
La Jolla, California

cover img faculity

Joshua Sabari, MD

Assistant Professor of Medicine
Thoracic Medical Oncology
Phase I Experimental Therapeutics
Perlmutter Cancer Center
NYU Langone Health
New York, New York

Provided by

ProCE Banner

Supporters

Supported by educational grants from

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Lilly

Novartis Pharmaceuticals Corporation

Turning Point Therapeutics Inc